Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points

Executive Summary

First-quarter results of frontline Indian firms are expected to be a mixed bag as some are boosted by launches of products with marketing exclusivity in the US, while others are weighed down by increased competition and pricing erosion in the base business. Updates on compliance efforts at facilities and evolving regulations in India – the ban on certain fixed-dose combinations and controversial pricing orders – are other key issues to look out for.

Advertisement

Related Content

Operational Fixes At Cipla But All Eyes On Generic Advair
Generic Glumetza Scripts Lupin's Strong US Run
Venezuela Hits Dr. Reddy’s Profit, But Indicators Brighter
Here Comes Sun’s US Cost-Saving Gleevec Generic

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel